BIOMAT Database Logo BIOMAT Database Logo

Specific suppression of the antibody response to acetylcholine receptor in vitro and in vivo by daunomycin-acetylcholine receptor conjugates. 1988

D Shelton, and Y Fujii, and W Knogge, and J Lindstrom
Salk Institute for Biological Studies, San Diego, California 92138.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

D Shelton, and Y Fujii, and W Knogge, and J Lindstrom
Suppression of anti-hapten antibody response in vitro by hapten-carrier conjugates.
September 1977, European journal of immunology,
D Shelton, and Y Fujii, and W Knogge, and J Lindstrom
Suppression of antibody responses to the acetylcholine receptor by natural antibodies.
August 1989, European journal of immunology,
D Shelton, and Y Fujii, and W Knogge, and J Lindstrom
Immune responses in vitro. II. Suppression of the immune response in vitro by specific antibody.
August 1969, The Journal of experimental medicine,
D Shelton, and Y Fujii, and W Knogge, and J Lindstrom
Specific suppression of the antibody response in vitro by serum from paralyzed mice.
August 1975, Journal of immunology (Baltimore, Md. : 1950),
D Shelton, and Y Fujii, and W Knogge, and J Lindstrom
Acetylcholine receptor presentation by B cells using heterobifunctional antibody conjugates.
June 1993, Annals of the New York Academy of Sciences,
D Shelton, and Y Fujii, and W Knogge, and J Lindstrom
Suppression of immune responses to acetylcholine receptor by interleukin 2-fusion toxin: in vivo and in vitro studies.
February 1991, Journal of neuroimmunology,
D Shelton, and Y Fujii, and W Knogge, and J Lindstrom
In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody.
August 1990, The Journal of experimental medicine,
D Shelton, and Y Fujii, and W Knogge, and J Lindstrom
Specific suppression of the antibody response by antibodies to receptors.
September 1972, Proceedings of the National Academy of Sciences of the United States of America,
D Shelton, and Y Fujii, and W Knogge, and J Lindstrom
In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies.
January 1982, Immunological reviews,
D Shelton, and Y Fujii, and W Knogge, and J Lindstrom
Antigen-specific therapy of experimental myasthenia gravis with acetylcholine receptor-gelonin conjugates in vivo.
March 1993, European journal of immunology,
Copied contents to your clipboard!